Response to lebrikizumab in atopic dermatitis patients who failed upadacitinib: 48‑week real‑world outcomes

Supplementary Figure 1. The transition of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) during lebrikizumab treatment in patients with atopic dermatitis switched from upadacitinib 30 mg (n = 15, upper panels) or 15 mg (n = 21, lower panels). Range of box, middle line of box, and lower/upper of whisker represent interquartile, median, and minimum/maximum, respectively. Patients received lebrikizumab 500 mg at weeks 0 and 2, then 250 mg every 2 weeks until week 16, followed by every 4 weeks. TARC, IgE, and LDH decreased until week 48 in both groups. TEC peaked at week 4 in the 30 mg group and at week 12 in the 15 mg group, and then decreased to baseline.

补充图1。本图展示了既往接受乌帕替尼（upadacitinib）30mg治疗、后续转换为乐贝珠单抗（lebrikizumab）治疗的特应性皮炎患者（n=15，对应上图组），以及既往接受乌帕替尼15mg治疗、后续转换为乐贝珠单抗治疗的特应性皮炎患者（n=21，对应下图组）体内免疫球蛋白E（IgE）、胸腺活化调节趋化因子（TARC）、乳酸脱氢酶（LDH）与嗜酸性粒细胞总数（TEC）的动态变化。箱线图的箱体范围代表四分位数间距，箱体中线代表中位数，须线的上下端点分别对应最小值与最大值。两组患者的给药方案为：第0周与第2周给予500mg乐贝珠单抗，随后每2周给药250mg直至第16周，之后改为每4周给药一次。结果显示，两组患者的TARC、IgE及LDH水平均在第48周前持续下降；30mg组的TEC于第4周达到峰值，15mg组则于第12周达到峰值，随后回落至基线水平。